You are here

Model predicts 80% of patients with Crohn’s at risk for complications

CHICAGO — The PROSPECT model predicted more than 80% of patients with Crohn’s disease have a moderate to high risk of developing related complications within 3 years of analysis, according to data presented at Digestive Disease Week.“As we know, Crohn’s disease is a chronic, destructive disease that causes irreversible bowel damage in many patients,” Corey A. Siegel, MD, MS, from the Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, said during the presentation. “While damage typically happens early, there is a window of opportunity to prevent disease progression. We can get the…

Read More

Capsule endoscopy bests MRE in detecting proximal small bowel Crohn’s

CHICAGO — While capsule endoscopy, magnetic resonance enterography and small bowel intestinal contrast ultrasound resulted in comparable diagnostic yield for detection of small bowel Crohn’s disease, capsule endoscopy was superior to MRE for detecting proximal disease, according to research presented at Digestive Disease Week.A meta-analysis published 7 years ago in the American Journal of Gastroenterology demonstrated that capsule endoscopy was better than CT enterography and ileocolonoscopy, and had a similar yield to that of MRE, but since then additional studies have been performed and new diagnostic methodologies have emerged, Uri…

Read More

Family history of IBD linked to younger diagnosis, complications

CHICAGO — Researchers associated close-relative family history of Crohn’s disease with earlier diagnosis of Crohn’s disease in patients and increased risk of related complications while, overall, family history of inflammatory bowel disease predicted a younger age of diagnosis, according to data presented at Digestive Disease Week.“As we know IBD, which combines Crohn’s disease and ulcerative colitis, is a chronic, progressive disease and the incidence of IBD is still growing worldwide,” Nynke Z. Borren, MD, from the Massachusetts General Hospital, said in a presentation. “Genetic factors play an important role in…

Read More

Biosimilars unlikely to save costs as expected, experts say

Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to yield expected cost savings due to a number of state and payer policies, according to an opinion piece published in JAMA.However, cost-savings may be attainable after key challenges to biosimilar substitution are overcome, the authors concluded. FULL ARTICLE:

Read More

Xeljanz beats placebo in three ulcerative colitis trials – Healio

HealthDayXeljanz beats placebo in three ulcerative colitis trialsHealio“There is still a substantial unmet need for new treatments for patients with ulcerative colitis,” William J. Sandborn, MD, professor of medicine, chief of the division of gastroenterology and director of the University of California San Diego …Arthritis Drug Shows Promise for Ulcerative ColitisHealthDayall 4 news articles » FULL ARTICLE:

Read More
<< Go Back